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Background: The Arterovenous Loop (AV Loop) model is a vascularization model in tissue engineering research,
which is capable of generating a three dimensional in vivo unit with cells as well as the supporting vessels within
an isolation chmaber. In our previous studies the AV loop in the isolation chamber was discovered to undergo
hypoxia, characterized by Hypoxia Inducible Factor (HIF) up-regulation. The vascularization followed the increase of
HIF-α temporally, while it was spatially positively correlated with the HIF-α level, as well. This study aims to prove
that HIF-1a up-regulation is the stimulus for vascularization in the AV loop model.
Method: The AV loop model in rats was created by interposing a femoral vein graft into the distal ends of the
contralateral femoral artery and vein, and the loop was embeded in fibrin matrix and fixed in isolation chamber.
PHD (prolyl hydroxylases) inhibitor DMOG (Dimethyloxallyl Glycine) was applied systemically in the rats in 40 mg/KG
at day 0 and day 3 (DMOG-1), or in 15 mg/KG at day 8, day10 and day12 (DMOG-2). Two weeks later the
specimens were explanted and underwent morphological and molecular evaluations.
Results: Compared to the control group, in the DMOG-2 group the HIF-1α positive rate was siginicantly raised as
shown in immunohistochemistry staining, accompanied with a smaller cross section area and greater vessel density,
and a HIF-1α accumulation in the kidney. The mRNA of HIF-1α and its angiogenic target gene all increased in
different extends. Ki67 IHC demostrate more positive cells. There were no significant change in the DMOG-1 group.
Conclusion: By applying DMOG systemically, HIF-1α was up-regulated at the protein level and at the mRNA level,
acompanied with angiogenic target gene up-regulateion, and the vascularization was promoted correspondingly.
DMOG given at lower dosage constantly after one week tends to have better effect than the group given at larger
dosage in the early stage in this model, and promotes cell proliferation, as evidenced by Ki67 IHC. Thus, this study
proves that HIF-1a up-regulation is the stimulus for vascularization in the AV loop model and that the process of
the vessel outgrowth can be controlled in the AV Loop model utilizing this mechanism.
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Tissue engineering is a very promising technology but
until now has a limitation of obtaining large three dimen-
sional constructs with a reliable vascularization that would
resemble living tissue. In contrast to in vitro models, in
in vivo tissue engineering studies, the cells planted into* Correspondence: raymund.horch@uk-erlangen.de
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unless otherwise stated.the three-dimensional construct require a sufficient perfu-
sion from local blood capillary network [1]. As the basic
units that built up the organism, in most cases, the cells
draw their nutrition from the diffused molecules from the
blood capillaries that are no more than 200 μm away [2,3].
Thus, the key to successful tissue construction is to
vascularize the constructs quickly and efficiently.
The Arteriovenous Loop (AV Loop) model first de-
scribed in 1979 [4] is an in vivo vascularization model
for surgical purposes. It is composed by interposing ahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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eral femoral artery and vein, and then the loop is em-
bedded by specific matrixes within an isolation chamber,
where an axial vascularization is generated [5]. By ma-
nipulating the matrix and the chamber that hold the
loop, the model has been applied in various tissue engin-
eering studies. Lokmic et al investigated the spontaneous
microcirculatory development of the AV loop in a pro-
tected space within a polycarbonate chamber, suggesting
that the model possessed enormous potential by ma-
nipulating the chamber structure to conduct the growth
of the tissue to required directions [6]. The AV loop has
also been applied for bone tissue engineering with por-
ous solid matrices [7,8]. The model could also carry cells
suspended in soft matrix and provide an in vivo culture
platform thus possesses the potential to generate a target
organoid eventually. Brown et al seeded islet cells with
matrigel into the model and the cells survived 3 weeks
after implantation [9]. In another study on muscle tissue
engineering using the AV loop model, primary myoblasts
were seeded and later individual myoblasts fused to form
multinucleated myotubes [10].
The AV-loop model provides a highly vascular, isolated
tool for in vivo tissue engineering as well as angiogenesis
and anti – angiogenesis studies. The angiogenic property
is driven by different forces. Mechanical forces play
themselves an important role through shear stress in
producing a subcritical ischemic area where angiogenesis
and vasculogenesis must start. So angiogenesis and vas-
culogenesis can also be a physically (mechanically) in-
duced phenomenon from effects of turbulences and
shear stress [11].
The AV loop model is a protected space separated
from the surrounding tissue, and therefore is also a hyp-
oxic environment for the inner tissue and cells. Hence
the AV loop implanted in the isolation chamber is also a
hypoxic model [12-15]. Hypoxia Inducible Factor (HIF)
is a transcriptional factor that is the master regulator of
oxygen homeostasis and it also plays an essential role in
angiogenesis [16-18]. HIF consists of α and β subunits.
HIF-1α is one of the three isoforms of HIF-α, which is
most critical for hypoxic response [19]. There are over
100 angiogenic genes found up to date that are directly
or indirectly regulated by HIF-1α, such as Vascular
Endothelial Growth Factor-A (VEGF-A) [20] and Basic
Fibroblast Growth Factor (bFGF) [21].
The HIF-1α subunit is constantly expressed, but will
be degraded rapidly under normoxic condition. The Hy-
droxylases, mainly the Prolyl hydroxylase (PHD), [22]
are greatly involved in the degradation of HIF-1α. In
well-oxygenated cells, the prolyl hydroxylation is cata-
lyzed with the presence of Fe (II) and oxygen. Whereas
in hypoxia when the PHD is blocked or inhibited due to
lack of oxygen, HIF-1α is stabilized and dimerizes withthe β subunit, binds to target genes, and leads to the
downstream activations towards increase target gene
transcription.
The endogenous HIF-1α levels can be increased by the
suppression of PHD activity, either by reducing the cellu-
lar oxygen level or by combining the Fe (II) competitively.
Dimethyloxallyl Glycine (DMOG) is a cell permeable,
competitive inhibitor of the PHDs [23]. DMOG is an
analogue of 2-oxoglutarate, and in this way it inhibits not
only the HIF prolyl but also asparaginyl hydroxylases. Be-
side that it is predicted to inhibit other members of 2-
oxoglutarate-dependent dioxygenases. DMOG has been
proved to be able to stabilize HIF-1α both in vitro and
in vivo [24-27], which can be superior to adding limited
kinds of growth factors [28] (Figure 1).
HIF-1α could accumulate in the nuclei of the hypoxic
cells and the protein can be detected by immunohisto-
chemistry staining. In our previous study, the loop
sealed in the isolation chamber was discovered to
undergo hypoxia, characterized by HIF-1α up-regulation
[29]. The vascularization followed the increasing of HIF-
1α temporally, while spatially it was positively correlated
with the HIF-1α level, as well (Data not shown). Thus,
to prove the hypothesis, the PHD inhibitor DMOG
was applied to stablize the HIF-1α, to see weather the
increase of HIF-1α would induce the increase of
vascularization in the AV loop.
Methods
Animal model preparation
Syngenic male Lewis rats at 300 g (Charles River GmbH,
Sulzfeld, Germany were used in the experiment. The rats
were specific pathogen free (SPF), kept with optimized
and standardized animal housing. Ethical rules have
been followed during the whole research.
All surgeries were performed under magnification with
the same microscope (OPMI Vario 700, Karl Zeiss, Jena,
Germany) by the same micro surgeon. The rat was laid
on the back on the warming plate at 37°C under anaes-
thesia with 2% Isoflurane inhalation (Figure 2a). The left
femoral vessels were exposed by the incision on the mid-
dle of the thigh, with the vasa vasorum removed and
branches coagulated. The 1.5 cm vein graft was harvested
from the contralateral femoral vein in the same way
and was interposed between the distal ends of the left
femoral artery and vein (Figure 2b). 11-0 suture (Ethicon,
Norderstedt, Germany) was used to inosculate the end-to-
end anastomosis. When the loop was accomplished, it
was then placed in a cylindrical Teflon chamber, fixed
by 4 stabs and embedded by 720 ul fibrin gel made up
of 4 IU/ml fibrinogen and 2 IU/ml thrombin (Tisseel VH
S/D, Baxter Healthcare S.A., Wallisellen, Switzerland)
(Figure 2c). The chamber was sealed by a Teflon lid with
6-0 suture (Ethicon) and fixed on the thigh with 3-0
Figure 1 The Hydroxylase pathway of HIF-1α and DMOG structure. The Prolyl hydroxylase (PHD) is catalyzed with the presence of oxygen
and Fe (II), then subsequently involved in the HIF protein degradation. Otherwise, HIF-1α is stabilized and dimerized with the HIF-β, and activates
the target genes. DMOG structure (From SciFinder®).
Figure 2 The surgical procedures of AV Loop preparation. A) Incisions on the thighs. B) The AV Loop: A = artery, V = vein, G = graft from the
contralateral femoral vein. C) Loop fixed in the chamber, embedded by fibrin clot. D) The isolation chamber covered by the lid and fixed on the
left thigh. P = pedicle.
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rat was given 60 I.U. heparin subcutaneously and antibi-
otics (Veracin compositum) 0.2 ml intramuscularly. The
wound was covered by Aluminum spray.Group settings and drug administration
The rats were randomly allocated into 3 groups:
1) control group (n = 6),
2) DMOG-1group (n = 6): DMOG 40 mg/kg, i.p. at day
0 and day 2,
3) DMOG-2 group (n = 6): DMOG 15 mg/kg, i.p. at day
8, day 10 and day 12.
DMOG (cayman, 71210) was freshly dissolved with sa-
line before use. The animals underwent an observation
period of 2 weeks. Upon the date for explantation, the
distal 2/5 of the specimens were frozen in liquid nitro-
gen, stored in -70°C fridge before sent to further RNA
isolation and qPCR analysis. The proximal 3/5 of the
specimens was fixed in 4% PFA for routine histology
analysis. Kidneys were also kept as organ control to see
the DMOG remained systemically.Immunohistochemistry
ROI
Transverse section across the central was picked, (Figure 3).
In each slide, the ROI were taken in 4 directions from the
central vessels.
The plane in the picture demonstrated the slide cut in
the middle of the clot. As the blade cut across the speci-
men, the transverse section was harvested, which was
marked with red board.Figure 3 The cutting plane in the fibrin clot containing a loop.
The plane in the picture demonstrated the slide cut in the middle of
the clot. As the blade cut across the specimen, the transverse
section was harvested, which was marked with red board.HIF-1α IHC
The staining was performed with Dako Catalyzed Signal
Amplification (CSA) system (K1500) based on “ABC
method”. After the 7 min cooking in pressure cooker at
121°C for antigen retrieval, The slides were successively
blocked with Peroxidase Block for 10 min, Avidin Block
(Vector Avidin/Biotin blocking Kit) for 20 min, Biotin
block(Vector Avidin/Biotin blocking Kit) for 20 min and
Protein Block (CSA kit) for 30 min. The slides were sub-
sequently incubated with the primary antibody Poly-
clonal rabbit anti HIF-1α (Cayman 10006421) in 1:50000
dilution in 2 ~ 8°C fridge overnight, and then the sec-
ondary antibody Biotinylated polyclonal Goat anti Rabbit
(Dako E0432) in 1:2000 dilution in 2% rat serum for
15 min in room temperature, succeeding the incubation
of Strepavidin-Biotin Complex (SBC, from CSA kit, pre-
pared 30 min before use), Amplification reagent (CSA kit)
and Strepavidin-Peroxidase (CSA kit) for 15 min separ-
ately. In the end the slides were developed by DAB.
Lectin IHC
Cross sections were cut from the central part of the
Loop and Lectin IHC was performed. The newly grown
vessels in the granulation tissue in the AV loop were
Lectin IHC positive, appeared in brown lining in lumens.
After the pictures of each slide were taken by camera
with the Leica application software, the area of cross sec-
tion was measured by Leica application software. The
absolute vessel number was counted manually and by
dividing it to the cross section area, the vessel density
was calculated as well.
The slides were cooked in pressure cooker for 1 min
for antigen retrieval. Isolectin B4 Biotinylated antibody
(Bandeiraea Simplicifolia Sigma L2140) was diluted to
1:250 with Tris buffer, incubated in 2 ~ 8°C fridge over-
night, following the reaction with Streptavidin-peroxidase
for 30 min. The signal was developed by DAB for approxi-
mately 10 min.
Ki67 IHC
After 1min cooking in high pressure cooker, the staining
was performed with Polymer kit (ZytoChem Plus AP
Polymer Kit), using the antibody Monoclonal rabbit anti
Ki67 (Zytomed RBK 027) in 1:200 dilution, and devel-
oped by Fast red.
Generally, unless specifically stated, the slides were in-
cubated horizontally at room temperature (20°C). After
the incubations there were three times of bath in Tris-
tween buffer, only the rinse after the blocking applied
Tris buffer without tween.
Real-time Polymerase chain reaction (PCR)
RNA was isolated with the RNeasy® Fibrous Tissue Midi kit
(Qiagen, Hilden, Germany) according to manufacturer’s
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RNA with random hexamer priming and the RevertAid™
First Strand cDNA Synthesis Kit (Thermo Scientific, Inc.,
Waltham, MA, USA). Real time PCR was performed in
a CFX96 Touch™ Real-Time PCR Detection System
and analyzed with the CFX Manager™ Software (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). The 20 μl total re-
action volume in each well of 96-well plate included: 10 μl
SsoAdvanced™ SYBR® Green Supermix, 0.6μl forward pri-
mer, 0.6 μl reverse primer, 7.8 μl nuclease-free water, and
1 μl cDNA (25 ng). The amount of each transcript was
normalized to GAPDH. The mRNA expression of the
control loop served as control and was set as 1. The
calculation of the expression ratios was performed
using the comparative Ct-method. Following is the list























Pictures for the ROI were taken by the same microscope
(Zeiss Carl Zeiss Meditec Vertriebsgesellschaft mbH,
Oberkochen, Germany). The measures of the area of the
clot were made by the software Leica Application (Leica
Microsystems, Wetzlar, Germany). The counting of the
vessels and cells in each ROI was made manually by
blind tester. Statistical analysis was performed using Stu-
dent’s-Test and with SPSS. P < 0.05 was considered of
statistical significance and labeled.
Research involving human subjects
There was no Research involving human subjects (in-
cluding human material or human data) that is reported
in the manuscript.All experiments were approved by the animal care
committee of the University of Erlangen and the Gov-
ernment of Mittelfranken, Germany (54-2532.1-28/09).
Results: (whole section was reorganized)
Systemic and local effects of DMOG: HIF-1α is positive
in DMOG-2 group in kidneys and HIF-1α positive cells
increased significantly in DMOG-2 group in the AV loop
The effect of the systemic application of DMOG can
only be shown in DMOG-2 group. As HIF-1α accumu-
lated in the nuclei in hypoxic cells, the positive signal
appeared in intensive brown in IHC staining. In DMOG-1
group (DMOG given at day 0 and day 2 at 40 mg/Kg)
HIF-1α IHC was negative at day 14. However, in DMOG-
2 group (DMOG given at day 8, 10, and 12 at 15 mg/Kg) a
few HIF-1α positive cells in the kidney can be observed
(Figure 4 A,B,C).
Beside systemically effects of DMOG HIF-1α positive
cells increased significantly in DMOG-2 group in the
AV loop (Figure 4D).
8 ROIs were taken in each slide, in 4 directions from the
central artery and vein. In each picture, HIF-1α positive
cell number and total cell number were counted manually
and the percentage of HIF-1α cells was calculated. Com-
paring to the control group, the DMOG-2 group had 48%
HIF-1α positive cells, which is significantly higher than
the control group that had 10% HIF-1α positive cells out
of the total cell ingredients (* P < 0.05).
DMOG effects on the vascularisation in the AV loop:
higher vessel density and smaller cross section area in
DMOG-2 group
Comparing to the other groups, the DMOG-2 group
possessed a significantly smaller cross section area.
(17.8 × 106μm2, 14.4 × 106μm2 versus 9.4 × 106μm2, *,# p <
0.05). The cross section area of the control group was
bigger than the experimental groups (Figure 5A).
As for the absolute vessel number, no significance was
found between the control group (212/cross section),
the DMOG-1 group (229/cross section) and DMOG-2
group (272/cross section), but a trend could be observed
that the DMOG-1 group tend to have more vessels than
the control group, whereas the DMOG-2 group possessed
the most vessels (Figure 5B).
The DMOG-2 group significantly possessed a higher
vessel density (3.0 × 10-5/μm2)than the control group
(1.2 × 10-5/μm2, *p < 0.05) and the DMOG-1 group
(1.6 × 10-5/μm2 , #p < 0.05) (Figure 5c).
DMOG effects on cell proliferation in the AV loop: Ki67
IHC: more positive cells in DMOG-2 group
Ki67 is a nucleus protein that is associated with cell prolif-
eration activity [30]. In Ki67 IHC staining, positive cells
were red in nuclei whereas the negative cells counter
Figure 4 HIF-1α IHC for kidney (×200) and Percentage of HIF-1α positive cells in the AV loop. The HIF-1α IHC for kidneys taken under ×200
magnification. In control group (A) and DMOG-1 group (B) the kidneys were negative. In DMOG-2 group (C) HIF-1α positive cells were intensive
brown in nuclei (pointed by arrows). (D) The slides from the central part of the Loop was cut and stained for HIF-1α IHC. In each slide 8 ROIs
were taken from the up, down, left and right direction to the central artery or vein under x400 magnification. The brown nuclei cells recognized
as HIF-1α positive cells and the blue nuclei cells recognized as HIF-1α negative cells, so the percentage of percentage of HIF-1α positive cells
could be calculated. The DMOG-2 group that received DMOG i.p. injection in 15mg/KG at day 8, day10 and day12 had a higher HIF-1α positive
rate than the control group. (48% versus 10% , *p < 0.05).
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positive cells were observed in DMOG-2 group all over the
slide, (Figure 6: control group artery and vein/DMOG-1
group artery and vein/DMOG-2 group artery and vein) in-
dicating that DMOG may not result in the depression of
proliferation of cells in vivo.
DMOG effects on angiogenic gene expression levels in
the AV loop: real time PCR: mRNA of HIF-1α and its
angiogenic target genes increased
The distal 2/5 part of the fibrin clot containing the AV
loop as the vascular outgrowth from the axial loop was
sent to RNA isolation, the mRNA of HIF-1α as well as
its target genes that were considered to be related to
angiogenesis, including: eNOs, VE cadherin, VEGF, Flt-1,
and vWF were quantified by real time PCR [31]. Thegraph below demonstrates the mRNA levels of DMOG-
2 group compared to the control group in folds. The
HIF-1α elevated more than 10 folds in the DMOG-2
group. Correspondingly, its target genes elevated to dif-
ferent extends. In particular the vWF raised significantly
(*P < 0.05) (Figure 7).
Discussion
The AV loop model is a promising vascularization model
in the in vivo tissue engineering studies. The loop under-
went hypoxia in the isolation chamber and the hypoxia pat-
tern may have some relationship with the vascularization
process according to our previous study which investigated
the hypoxia pattern in the AV Loop spatially and tempor-
ally. The present study intends to prove, that the PHD in-
hibitor DMOG could be able to stimulate the vessel
Figure 5 Cross section area/absolute vessel number/vessel
density in cross section. Cross section was cut from the central
part of the Loop and Lectin IHC was performed. The cross section
area was measured by Leica application software A). Cross section
area (μm2): the DMOG-1 group (14.4 x106μm2) tended to be smaller
than the control group (17.8 x 106μm2) and bigger than the DMOG-2
group (9.4 x 106μm2), but no statistic significance was found. The
DMOG-2 group shrinks significantly comparing to the other groups.
B). absolute vessel number: no significance was found between
the control group (212 /cross section), the DMOG-1 group (229 /cross
section) and DMOG-2 group (272/ cross section), but a trend could be
observed that the DMOG-1 group tend to have more vessels than the
control group, whereas the DMOG-2 group possessed the most vessels.
C). vessel density in cross section: The DMOG-2 group significantly
possessed a higher vessel density (3.0 x 10-5/μm2) than the
control group (1.2 x 10-5/μm2, *p < 0.05) and the DMOG-1
group (1.6 x 10-5/μm2 #p < 0.05).
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hence to prove that HIF-1α is the stimulus for
vascularization in the AV loop model. Beside effects of
hypoxia angiogenesis and vasculogenesis can also be a
mechanically induced phenomenon from effects of turbu-
lences and shear stress [11]. Mechanical forces themselves
can play an important role through shear stress in produ-
cing a subcritical ischemic area where angiogenesis and
vasculogenesis must start.
PHD inhibitor up-regulate HIF-α
The PHD inhibitor has been used as HIF-α stabilizer to
suppress the HIF-α degradation by hydroxylase pathway
in studies that needs to up-regulate HIF-α. Warnecke
et al had successfully induced HIF-α expression in vivo
and in vitro. The renal HIF-α was increased and by re-
peated local injection into the sponge that was embedded
subcutaneously, angiogenesis was induced [32]. Song et al
had dissolved DMOG in PBS and delivered DMOG to rats
in 15 mg/kg/day via an osmotic pump and had a renopro-
tection and HIF-α induction accompanied by a reduction
of oxidative stress, inflammation and fibrosis [25]. Nagel
et al discovered that DMOG given to rats at 0 h,8 h and
16 h postoperatively in 40 mg/kg by i.p. injection helped
to improve the behavior after brain ischemia [24]. This
study proved that in the early stage (upon 2 weeks of im-
plantation) vascularization process in the AV loop could
be accelerated by the PHD inhibitor DMOG, with smaller
dosages maintained in the system, accompanied with the
HIF-1α protein increase.
Kinetics of DMOG in rat
DMOG given at lower dosage constantly after one week
tend to have better effect than the group given at larger
dosage in the early stage in this model. Till now the kin-
etics in the rat is still unclear, either from the manufac-
turer or from the literature. What we do know is that
according to the molecular structure provided by the
manufacturer (Figure 1), this chemical possesses strong
polarity, which means it is highly soluble in water. It
may not be active in solution for over one week, and it
chelates with Fe (II) rapidly and strongly.
Since the fibrin matrix is porous [33] and proved to be
able to function as slow release system for growth fac-
tors such as VEGF and bFGF [34], it may be also inter-
esting that whether DMOG can be loaded in the matrix
upon the implantation of the AV Loop, and be released
later on. In the preliminary experiment the DMOG was
dissolved in fibrin in different dilution in Teflon cham-
bers and imbedded in as up-side-down manner as de-
scribed before [35] and the dorsal muscle that attach to
the fibrin clot were examined at day 7 and day 1, and
there was no sign of HIF-1α up-regulation or increase of
vascularization (data not shown).
Figure 6 Ki67 Immunohistochemistry staining. The slides were picked from the central transversal section, and stained for Ki67 which was a
proliferation indicator located in the nuclei. Positive cells were rosa red in nuclei while the negative cells were blue. Pictures from the central
artery and vein were taken for each group. A few positive cells could be found in the control group and DMOG-1 group, and tremendous
positive cells could be found in the DMOG-2 group, indicating that in the DMOG-2 group the proliferation of the cells were more active.
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i.p. injection. As the Kidneys were sensitive to DMOG,
[32] [25] it was utilized as organ control to indicate the
systemic level of drug. In this study, kidneys from both
of the control group and the DMOG-1 group were nega-
tive whereas in DMOG-2 group positive cells were ob-
served, indicating that DMOG would be degraded or
expelled from the system within days, and won’t main-
tain for more than a week. From this we can infer thatFigure 7 mRNA normalized fold expression. The DMOG-2 group was gi
(n = 6). The specimens were explanted at day 14 and the distal 2/5 part of
levels of HIF-1α, eNOs, VE cadherin, VEGF, Flt-1, and vWF expressed as foldadministrate the drug continuously or repeatedly, rather
than in a shock therapy would maintain this drug in sys-
tem as long as possible. The time points of applying the
drug are also important in this study. According to the
previous investigation for the pattern of vascularization
of the AV Loop, there are few cells exudate from the
central vessels at the first week upon the loop implant-
ation. The granulation tissue which contains newly
grown vessels generate rapidly in the second week whenven DMOG in 15 mg/Kg by i.p. injection at day 8, day10 and day 12
the clots were sent to mRNA analysis. Data given are mean mRNA
increase above control group (*P < 0.05).
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So in the second week there are much more cells that
can be induced to accumulate more HIF-1α, and hence
more tremendous outcome in vessel outgrowth.
Further effects of PHD
As the PHD family inhibit HIF-α via competitively che-
lating the Fe (II), which is an essential co-factor for
many enzymes [36], they may have effects in diverse
physiological activities which those enzymes are involved
in. In Song’s study the DMOG treatment decreased
macrophage infiltration and reduced fibrosis [27]. How-
ever, in our study, the Ki67 IHC which indicates the cell
proliferation [30] demonstrates that DMOG does not in-
hibit the proliferation but on contrary activate the mi-
tosis of the infiltrating cells in the fibrin matrix.
In this study, the HIF-1α was up-regulated at protein
level, but also at the mRNA level, indicating that DMOG
may be also involved in the HIF-α up-regulation tran-
scriptionally, aside from stabilizing the protein from
hydroxylation.
Perspectives
In order to generate a three dimensional construct, it
seems necessary that cultured cells are seeded into a scaf-
fold that can mimic the structure and the environment for
cell growth, and allow the exchange of oxygen, nutrient
and the waste. As an in vivo animal model for tissue
engineering, specific cells can be seeded in the chamber to
generate corresponding tissue or organ [9,10]. As an
in vivo model, the knowledge about the vascularization
pattern corresponding to hypoxia and HIF-1α expression
can help modulate the vascular growth. Since bFGF and
VEGF immobilized in the fibrin matrix can improve the
vascularization of AV loop [34] and it may be a superior
choice to manipulate the neo vessel outgrowth by up-
regulation their transcription factor HIF-1α [28], the PHD
inhibitor is a good option.
Summary
The PHD inhibitor DMOG was utilized as HIF-1α stabli-
zer in the study. DMOG was applied in two ways: at early
stage (day 0, day3) of the loop in larger dosage (40 mg/kg),
or at later stage (day 8, day 10, day 12) in smaller dosage
(15 mg/kg), namely DMOG-1 group and DMOG-2 group.
Upon the explantation at day 14, DMOG was only still
functioning in the system in DMOG-2 group. This was
evidence by the HIF-1α IHC for the kidneys that were sen-
sitive to the PHDs stimulation that HIF-1α positive renal
cells were only observed in DMOG-2 group.
Also, in DMOG-2 group the HIF-1α positive cell per-
centage raised significantly and mRNA was over 10 folds
over the control group, indicated that HIF-1α was up-
regulated at protein level and mRNA level. The mRNAof its angiogenic target genes such as eNOs, VE cad-
herin, VEGF, Flt-1, and vWF were up-regulated as well.
The cross section area decreased and the vessel denstiy
increased in DMOG-2 group, hint that the fibrin clot
was degraded faster and the vascularization more active.
Addistional evidence was the Ki67 IHC which could
demonstrate the activuty of cell proliferation. In DMOG-2
group there were tremendous Ki67 positive cells compar-
ing to the control group and the DMOG-1 group.
Conclusions
In summary the process of the vascularization can be
stimulated by DMOG in the AV Loop model. DMOG
given at lower dosage constantly after one week tends to
have better effect than the group given at larger dosage
in the early stage in this model, and promotes the cell
proliferation.
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